<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175863">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806234</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH080270</org_study_id>
    <secondary_id>R01MH080270</secondary_id>
    <secondary_id>DSIR 84-CTS</secondary_id>
    <nct_id>NCT00806234</nct_id>
  </id_info>
  <brief_title>Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Zucker Hillside Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of two different treatments for children and
      adolescents who have gained weight on their antipsychotic medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disorders that involve severe dysregulation of mood or thoughts in children -- such as early
      onset bipolar spectrum (BPS) and schizophrenia spectrum (SS) disorders -- are commonly
      treated with antipsychotic medications. However, many of the newest and most commonly
      prescribed antipsychotic medications can cause weight gain and metabolic dysfunctions. Use
      of these newer antipsychotics, called second generation antipsychotics (SGAs), is increasing
      rapidly in children, and the risk of weight gain from SGAs is higher among children than
      adults. Excessive weight gain can lead to obesity, which, in turn, can lead to increased
      health care costs, increased risk of sickness, and lower life expectancy. These factors are
      enhanced in children and adolescents who grow up obese.

      Two different strategies to reduce weight gain and metabolic side effects from SGAs will be
      tested in this study. The first strategy involves switching from the current SGA to a lower
      risk agent (aripiprazole or perphenazine) hypothesized to result in weight loss and improved
      metabolic functioning. The second strategy involves taking the medication metformin in
      addition to the current SGA. Metformin is approved by the Food and Drug Administration (FDA)
      to promote weight loss in youth with diabetes and has been effective in reducing weight in
      youth taking SGAs.

      Participation in this study will last between 26 and 27 weeks and will be divided into two
      parts. The first part will last 2 to 3 weeks and include three study visits. During this
      part, participants will undergo a physical exam, an electrocardiogram (EKG), a dual energy
      X-ray absorptiometry (DXA) test, and blood tests. The DXA measures body fat.

      The second part will last 24 weeks and include nine study visits. During this part,
      participants will be randomly assigned to one of three conditions: gradual switch of current
      SGA medication to either aripiprazole or perphenazine, addition of metformin to current SGA
      medication, or no change to treatment with current SGA medication. Visits will take place on
      Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24. At each visit, participants will meet with a study
      doctor who will assess symptoms and side effects, and participants and their guardians will
      receive information and recommendations about childhood obesity and weight loss. There will
      also be monthly urine pregnancy tests, and two blood tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index (BMI) z-score change</measure>
    <time_frame>Measured at Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat mass</measure>
    <time_frame>Measured at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body insulin sensitivity index</measure>
    <time_frame>Measured at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride levels</measure>
    <time_frame>Measured at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein (LDL)-cholesterol level</measure>
    <time_frame>Measured at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic syndrome</measure>
    <time_frame>Measured at Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will continue on current antipsychotic medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will add metformin to current antipsychotic medication treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole or Perphenazine</intervention_name>
    <description>Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Abilify, Trilafon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine</intervention_name>
    <description>Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zyprexa, Seroquel, Risperdal, Geodon, Abilify, Saphris, Sycrest, Fanapt, Fanapta, Zomaril, Latuda, Invega, Symbyax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM diagnoses that have an FDA indication for atypical antipsychotic use for at least
             one agent in the respective pediatric or adult age group. Specifically, primary
             DSM-IV diagnosis of Early Onset Schizophrenia Spectrum (EOSS; schizophrenia,
             schizoaffective disorder, schizophreniform disorder, psychotic disorder NOS); Bipolar
             Spectrum (bipolar I, II and NOS); Major depressive disorder with psychosis; Mood
             disorder NOS corresponding to Leibenluft and colleagues severely mood dysregulated
             (SMD) broad spectrum bipolar disorder; Mood disorder NOS corresponding to
             irritability associated with autism spectrum disorders; or - for adult teen
             participants aged 18-19 years - Major depressive disorder. Diagnoses will be
             determined by clinical interview, Leibenluft's modification of the K-SADS-PL, and the
             &quot;Aberrant Behavior Checklist&quot; (cutoff score of 18, as used by FDA for approval of
             risperidone and aripiprazole in minors).

          -  Clinically stable on current treatment regimen for at least 30 days, as assessed in a
             three-step process

          -  Current SGA treatment with olanzapine, quetiapine, risperidone, ziprasidone
             aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or
             olanzapine/fluoxetine for â‰¥ 8 weeks

          -  Stable dose of current SGA and psychotropic co-medications for at least 30 days

          -  Body mass index (BMI) at least in the 85th percentile for age and gender

          -  Substantial weight gain over the previous 3 years while taking a SGA, as reflected by
             family and referring physician's judgment. The weight gain did not have to occur on
             the child's current SGA. Weight needs to have remained stable or increased over past
             year.

          -  Agrees to use two effective forms of birth control or to remain abstinent

          -  Has a primary caretaker who has known the child well for at least 6 months before
             study entry

          -  Primary caretaker is able to participate in study appointments as clinically
             indicated

        Exclusion Criteria:

          -  Treatment with any medication (other than the currently prescribed psychotropic
             medications) that would significantly alter glucose, insulin, or lipid levels.
             Exception: orlistat and amantadine are permitted if the individual has taken the drug
             for at least one year without weight loss.

          -  Major neurological or medical illness that affects weight gain or that would prevent
             participation in physical activities

          -  Fasting glucose levels indicating need for prompt treatment

          -  Pediatrician or pediatric gastroenterologist recommendation to address abnormal
             fasting labs by pursuing more active treatment than those in the 2007 American
             Medical Association guidelines

          -  Diagnosis of anorexia nervosa or bulimia nervosa, as based on current or lifetime
             DSM-IV criteria

          -  Diagnosis of substance dependence disorder (other than tobacco dependence) within the
             past month, as based on DSM-IV criteria

          -  Positive urine toxicology indicating ongoing use of illicit substance

          -  Current treatment with more than one antipsychotic medication

          -  Current treatment with more than 3 total psychotropic medications (i.e., 2
             psychotropics plus SGA), with the exception of subjects taking 2 medications for ADHD
             in which a total of 4 psychotropic medications are allowed.

          -  Known hypersensitivity to metformin

          -  Prior treatment with aripiprazole and perphenazine for more than 2 weeks that was
             stopped for inefficacy or intolerability

          -  Pregnant, breastfeeding, or unwilling to comply with contraceptive requirements of
             study

          -  IQ score less than 55

          -  Significant risk of dangerousness to self or to others that would make study
             participation inadvisable

          -  Language issues that prevent child and/or parent from completing assessments or
             treatment

          -  Ongoing or previously undisclosed child abuse requiring new department of social
             service intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Reeves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linmarie Sikich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Division of Child and Adolescent Psychiatry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Correll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Zucker Hillside Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark A. Riddle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Division of Child and Adolescent Psychiatry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC, Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health. 2013 Aug 15;7(1):31. doi: 10.1186/1753-2000-7-31.</citation>
    <PMID>23947389</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Mark Riddle, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Weight Gain</keyword>
  <keyword>Obesity</keyword>
  <keyword>IMPACT</keyword>
  <keyword>Antipsychotic Treatment</keyword>
  <keyword>Excessive Weight Gain Associated With Antipsychotic Treatment</keyword>
  <keyword>Hybrid Efficacy/Effectiveness Design</keyword>
  <keyword>Reducing Weight Gain</keyword>
  <keyword>Improving Metabolic Parameters</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Metformin</keyword>
  <keyword>Risperdal</keyword>
  <keyword>Seroquel</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Zyprexa</keyword>
  <keyword>Geodon</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Abilify</keyword>
  <keyword>Trilafon</keyword>
  <keyword>Perphenazine</keyword>
  <keyword>Glucophage</keyword>
  <keyword>Paliperidone</keyword>
  <keyword>Olanzapine/fluoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Perphenazine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
    <mesh_term>Asenapine</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
